1.
COST EFFECTIVENESS ANALYSIS FOR PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS INFECTION IN HIGH-RISK CHILDREN IN THE DUTCH HEALTHCARE SETTING
PIH1 COST-EFFECTIVENESS MODEL OF PALIVIZUMAB IN THE NETHERLANDS